Distalmotion Raises $150 Million to Accelerate U.S. Expansion of DEXTER® Robotic Surgery System

Switzerland-based MedTech company Distalmotion has raised $150 million in Series G funding to drive U.S. market expansion of its DEXTER® robotic surgery system. The round was led by Revival Healthcare Capital with continued participation from existing investors. The funding will support commercial adoption in the United States, ongoing clinical programs, and product development initiatives.

A key area of focus for the expansion is the Ambulatory Surgery Center (ASC) segment, one of the fastest-growing sectors in surgical care as the industry continues its shift toward outpatient procedures. “This funding marks another important milestone on our journey,” said Greg Roche, CEO of Distalmotion. “The continued commitment of our investors validates our vision to break down barriers to robotic access through simplified operations. As we enter our next phase of U.S. market acceleration, ASCs represent a tremendous opportunity for DEXTER. The ongoing support from our investors reaffirms our roadmap, our mission, and the value DEXTER brings to minimally invasive surgery.”

In conjunction with the financing, the company appointed Chas McKhann as Executive Chairman of the Board. McKhann brings more than 25 years of leadership experience in MedTech and life sciences, having previously served as CEO of Apollo Endosurgery and Silk Road Medical. “I am thrilled to join the Distalmotion team,” McKhann said. “Distalmotion has reimagined how robotic surgery can be adopted across care settings because DEXTER delivers all the benefits of robotic surgery – dexterity, precision, and ergonomics – while also offering flexibility, efficiency, and value. With the recent FDA clearance in gynecology and release of DEXTER product enhancements, the company is poised to accelerate adoption in the U.S. and globally at this pivotal stage in its growth trajectory.”

DEXTER has already been adopted in clinical practices across Europe and the U.S., with nearly 3,000 patients treated. The soft tissue robotic system offers a simplified and mobile design, integrating easily into any operating room without major modifications. Its open architecture allows compatibility with existing surgical technologies and supports hybrid workflows between laparoscopic and robotic techniques.

With strong investor backing and clinical traction, Distalmotion is positioning DEXTER as a versatile solution to expand access to robotic-assisted surgery in hospitals and outpatient centers globally.